<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03280407</url>
  </required_header>
  <id_info>
    <org_study_id>S-20160158</org_study_id>
    <nct_id>NCT03280407</nct_id>
  </id_info>
  <brief_title>NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer</brief_title>
  <acronym>NEOLAR</acronym>
  <official_title>NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer: a Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zealand University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zealand University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main clinical hypothesis is that compared to radio-chemotherapy for low and mid rectal&#xD;
      tumors or surgery for high rectal tumors neoadjuvant chemotherapy reduces the rate of distant&#xD;
      relapse without increasing the rate of local relapse.&#xD;
&#xD;
      The aim of the present study is to compare long term and short term outcomes in rectal cancer&#xD;
      patients undergoing standard treatment (radio-chemotherapy/surgery) or experimental&#xD;
      neoadjuvant chemotherapy/surgery Furthermore, early surgical and medical complications, the&#xD;
      functional outcome, toxicity and quality of life (QoL) may be improved if radiotherapy can be&#xD;
      avoided.&#xD;
&#xD;
      Exploratory analyses are planned in order to find potential predictive markers for selecting&#xD;
      patients to either radio-chemotherapy/surgery or neoadjuvant combination&#xD;
      chemotherapy/surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard treatment of locally advanced but resectable cancer in the middle or lower&#xD;
      rectum is preoperative radio-chemotherapy and in the upper part initial surgery. The clinical&#xD;
      benefit from radio-chemotherapy is primarily through a reduction in local relapse but the&#xD;
      treatment is associated with acute toxicity and long term functional dysfunction.&#xD;
      Subsequently, it is important to select patients with high risk of local relapse. Intense&#xD;
      systemic combination chemotherapy reduces the risk of distant relapse and increases survival&#xD;
      in the postoperative setting. The biological rationale is eradication of micrometastases and&#xD;
      hence it may be anticipated that earlier, i.e. neoadjuvant, combination therapy may improve&#xD;
      systemic control.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is an open label, randomized phase II screening trial allocating eligible patients to either standard treatment for rectal cancer or experimental preoperative combination chemotherapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>All patients will be evaluated with CT and MRI scans and clinically every 6 months for 2 years and annually until the number of events is reached and the trial is stopped (max 5 years)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>All patients will be evaluated with CT and MRI scans and clinically every 6 months for 2 years and annually for maximum 5 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local relapse</measure>
    <time_frame>5 years</time_frame>
    <description>Defined to be within the pelvis. Any relapse should be verified by biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant relapse</measure>
    <time_frame>5 years</time_frame>
    <description>Defined to be outside the pelvis. Any relapse should be verified by biopsy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluated using CTCEA (Common Terminology Criteria for Adverse Events) version 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluated using CTCEA version 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional outcome</measure>
    <time_frame>5 years</time_frame>
    <description>Measured with LARS questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>5 years</time_frame>
    <description>Measured with EORTC QoL questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Colorectal Neoplasm</condition>
  <condition>Colorectal Cancer</condition>
  <condition>Rectal Neoplasms</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Intestinal Disease</condition>
  <condition>Intestinal Neoplasms</condition>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>A, capecitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiochemotherapy with 50.4 Gy in 28 fractions concomitantly with chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B, FOLFOX or CAPOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy with CAPOX (oxaliplatin/capecitabine) or FOLFOX regimen (oxaliplatin/leucovorin/5FU), according to institutional practice</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d</description>
    <arm_group_label>A, capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFOX regimen (oxaliplatin/leucovorin/5FU)</intervention_name>
    <description>Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.</description>
    <arm_group_label>B, FOLFOX or CAPOX</arm_group_label>
    <other_name>FOLFOX (oxaliplatin/leucovorin/5FU)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAPOX (oxaliplatin/capecitabine)</intervention_name>
    <description>Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.</description>
    <arm_group_label>B, FOLFOX or CAPOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adenocarcinoma of the rectum with the lower boarder within 15 cm from the anal verge&#xD;
&#xD;
          -  Locally advanced tumor based on imaging&#xD;
&#xD;
          -  T3 tumors within 10 cm from the anal verge fulfilling the criteria for preoperative&#xD;
             radio-chemotherapy according to Danish Colorectal Cancer Group (DCCG) guidelines&#xD;
&#xD;
          -  T3c or T4 tumors 10-15 cm from the anal verge&#xD;
&#xD;
          -  Deemed resectable at the multidisciplinary team (MDT) conference&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  Adequate bone marrow, liver and renal function allowing systemic chemotherapy&#xD;
&#xD;
          -  Absolute neutrophil count ≥1.5x109/l and thrombocytes ≥ 100x109/l.&#xD;
&#xD;
          -  Bilirubin ≤ 1.5 x upper normal value and alanine aminotransferase ≤ 3 x upper normal&#xD;
             value&#xD;
&#xD;
          -  Calculated or measured renal glomerular filtration rate at least 30 mL/min&#xD;
&#xD;
          -  Anticonception for fertile women and for male patients with a fertile partner.&#xD;
             Intrauterine device, vasectomy of a female subject's male partner or hormonal&#xD;
             contraceptive are acceptable&#xD;
&#xD;
          -  Written and orally informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Distant metastasis&#xD;
&#xD;
          -  Invasive ingrowth into other organs&#xD;
&#xD;
          -  Incapacity, frailty, disability and comorbidity to a degree that according to the&#xD;
             investigator is not compatible with combination chemotherapy&#xD;
&#xD;
          -  Previous radiotherapy to the pelvis&#xD;
&#xD;
          -  Previous treatment with 5FU or oxaliplatin&#xD;
&#xD;
          -  Surgery within two weeks&#xD;
&#xD;
          -  Neuropathy NCI grade &gt; 1&#xD;
&#xD;
          -  Other malignant tumor within 5 years except non-melanoma skin cancer or carcinoma in&#xD;
             situ cervicis uteri&#xD;
&#xD;
          -  Pregnant (positive pregnancy test) or breast feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ismail Gögenur, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Surgery, ZUH</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lars Henrik Jensen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vejle Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ismail Gögenur, MD</last_name>
    <phone>+45 26336426</phone>
    <email>igo@regionsjaelland.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Henrik Jensen, MD</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Henrik Jensen, MD PhD</last_name>
      <email>lars.henrik.jensen@rsyd.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>September 7, 2017</study_first_submitted>
  <study_first_submitted_qc>September 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2017</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zealand University Hospital</investigator_affiliation>
    <investigator_full_name>Ismail Gögenur</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Neoadjuvant chemotherapy,</keyword>
  <keyword>locally advanced rectal cancer,</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>CAPOX (oxaliplatin/capecitabine)</keyword>
  <keyword>FOLFOX (oxaliplatin/leucovorin/5FU)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Undecided</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

